These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38423221)

  • 1. Colorectal neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm: Prognostic factors and PD-L1 expression.
    Ho YH; Hsu CY; Yau Li AF; Liang WY
    Hum Pathol; 2024 Mar; 145():80-85. PubMed ID: 38423221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of clinicopathological characteristics, therapeutic strategy and prognosis of 501 patients with gastric neuroendocrine neoplasms attending a single center].
    Zhang BL; Lu YX; Liang WQ; Gao YH; Xi HQ; Wang XX; Zhang KC; Chen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):459-466. PubMed ID: 37217354
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinicopathological features and prognostic factors associated with gastroenteropancreatic mixed neuroendocrine non-neuroendocrine neoplasms in Chinese patients.
    Huang YC; Yang NN; Chen HC; Huang YL; Yan WT; Yang RX; Li N; Zhang S; Yang PP; Feng ZZ
    World J Gastroenterol; 2021 Feb; 27(7):624-640. PubMed ID: 33642833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological characteristics of gastric neuroendocrine neoplasms: A comprehensive analysis.
    Zi M; Ma Y; Chen J; Pang C; Li X; Yuan L; Liu Z; Yu P
    Cancer Med; 2024 Feb; 13(4):e7011. PubMed ID: 38457192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF
    Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
    Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications of mismatch repair deficiency screening in patients with mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN).
    Lou L; Lv F; Wu X; Li Y; Zhang X
    Eur J Surg Oncol; 2021 Feb; 47(2):323-330. PubMed ID: 32907775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term surgical outcomes of gastric neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasms.
    Iwasaki K; Barroga E; Enomoto M; Tsurui K; Shimoda Y; Matsumoto M; Miyoshi K; Ota Y; Matsubayashi J; Nagakawa Y
    World J Surg Oncol; 2022 May; 20(1):165. PubMed ID: 35610656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroendocrine carcinoma and mixed neuroendocrine‒non-neuroendocrine neoplasm of the stomach: a clinicopathological and exome sequencing study.
    Ishida S; Akita M; Fujikura K; Komatsu M; Sawada R; Matsumoto H; Saegusa J; Itoh T; Kakeji Y; Zen Y
    Hum Pathol; 2021 Apr; 110():1-10. PubMed ID: 33359239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
    Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
    Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do neuroendocrine carcinomas and mixed neuroendocrine-non-neuroendocrine neoplasm of the gastrointestinal tract have the same prognosis? A
    Shi H; Qi C; Meng L; Yao H; Jiang C; Fan M; Pang S; Zhang Q; Lin R
    Ther Adv Endocrinol Metab; 2020; 11():2042018820938304. PubMed ID: 32670540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic features and lymph node metastasis pattern of the cervical MiNEN.
    Xu H; Zhao Z; Zhu Y
    Endocrine; 2022 May; 76(2):474-483. PubMed ID: 35102503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas.
    Lee SM; Sung CO
    Sci Rep; 2021 Mar; 11(1):6203. PubMed ID: 33737597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic and Molecular Characterization of Inflammatory Bowel Disease-Associated Neuroendocrine Carcinomas and Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms.
    Liao X; Schmidt AL; Zhang D; Li P; Wang X; Ko HM; Choi WT; Alpert L; Hao Y; Kovar-Peltz S; Polydorides AD; Wanjari P; Mastro J; Wang P
    Mod Pathol; 2024 Jul; ():100566. PubMed ID: 39025404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.
    Elvebakken H; Hjortland GO; Garresori H; Andresen PA; Janssen EAM; Vintermyr OK; Lothe IMB; Sorbye H
    J Neuroendocrinol; 2023 Apr; 35(4):e13256. PubMed ID: 37017614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.
    Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M
    Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 Expression in colorectal carcinoma and its correlation with clinicopathological parameters, microsatellite instability and BRAF mutation.
    Srivastava P; Husain N; Shukla S; Chauhan S; Pandey A; Masood S
    Indian J Pathol Microbiol; 2021; 64(3):490-496. PubMed ID: 34341259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling of pancreatic neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm.
    Kinowaki Y; Fukumura Y; Kawade G; Sugita K; Kinowaki K; Akahoshi K; Kobayashi M; Ono H; Kudo A; Tanabe M; Akashi T; Ohashi K; Kurata M
    Gene; 2024 Jan; 893():147916. PubMed ID: 37866661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.
    Rosenbaum MW; Bledsoe JR; Morales-Oyarvide V; Huynh TG; Mino-Kenudson M
    Mod Pathol; 2016 Sep; 29(9):1104-12. PubMed ID: 27198569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological features and lymph node and distant metastasis patterns in patients with gastroenteropancreatic mixed neuroendocrine-non-neuroendocrine neoplasm.
    Zhang P; Li Z; Li J; Li J; Zhang X; Lu Z; Sun Y; Li Y; Zhou J; Wang X; Peng Z; Shen L; Lu M
    Cancer Med; 2021 Jul; 10(14):4855-4863. PubMed ID: 34109756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma.
    Shimizu Y; Maruyama K; Suzuki M; Kawachi H; Low SK; Oh-Hara T; Takeuchi K; Fujita N; Nagayama S; Katayama R
    Cancer Lett; 2022 Sep; 543():215799. PubMed ID: 35724767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.